TRUVADA (emtricitabine/tenofovir disoproxil fumarate) tablets, for oral use Initial U.S. Approval: 2004

Category: .

TRUVADA (emtricitabine/tenofovir disoproxil fumarate) tablets, for oral use Initial U.S. Approval: 2004

INDICATIONS AND USAGE
HIV-1 Treatment
TRUVADA is a two-drug combination of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, and is indicated:
• in combination with other antiretroviral agents for the treatment ofHIV-1 infection in adults and pediatric patients weighing at least 17 kg.
HIV-1 PrEP :
• TRUVADA is indicated in at-risk adults and adolescents weighing atleast 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a negative HIV-1 test immediately prior to initiating TRUVADA for HIV-1 PrEP.
DOSAGE FORMS & STRENGTHS
Tablets: 200 mg/300 mg, 167 mg/250 mg, 133 mg/200 mg, and 100 mg/150 mg of emtricitabine and tenofovir disoproxil fumarate, respectively.
Manufactured By: Gilead Sciences, Inc.
Prescribing Information URL: Click Here

Access to TRUVADA® (emtricitabine/tenofovir disoproxil fumarate) tablets: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Emtricitabine/tenofovir, sold under the brand name Truvada among others, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. It contains the antiretroviral medications emtricitabine and tenofovir disoproxil. For treatment, it must be used in combination with other antiretroviral medications. For prevention before exposure, in those who are at high risk, it is recommended along with safer sex practices. It does not cure HIV/AIDS. Emtricitabine/tenofovir is taken by mouth.
Emtricitabine/tenofovir was approved for medical use in the United States in 2004. It is on the World Health Organization's List of Essential Medicines. In the United States, emtricitabine/tenofovir is under patent until 2020, but is available as a generic in the rest of the world.

Reviews

There are no reviews yet.

Add a review

FDA Approved Medicines Available
Generic Substitute Medicines
Abemaciclib Ado-Trastuzumab Docetaxel
Everolimus Gemcitabine Trastuzumab
Ribociclib Letrozole Olaparib
Paclitaxel Palbociclib Pertuzumab
Lapatinib Capecitabine Goserelin Acetate